Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,888488,excretion,Ketohexobarbital excretion in healthy subjects was in the range of 40-60% of dose.,[Metabolism of hexobarbital in patients with acute hepatitis and cirrhosis (author's transl)]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/888488/),%,40-60,20097,DB01355,Hexobarbital
,6864540,elimination half-lives,"The average elimination half-lives were 13.5 +/- 0.8 (n = 17) and 11.6 +/- 1.9 min (n = 21) (means +/- S.E.M.), respectively, whereas the systemic whole blood clearance values were 75.4 +/- 3.4 (n = 17) and 85.8 +/- 3.5 ml/min/kg (n = 21) (means +/- S.E.M.).","Disposition of hexobarbital in the rat. Estimation of ""first-pass"" elimination and influence of ether anesthesia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6864540/),min,13.5,20574,DB01355,Hexobarbital
,6864540,elimination half-lives,"The average elimination half-lives were 13.5 +/- 0.8 (n = 17) and 11.6 +/- 1.9 min (n = 21) (means +/- S.E.M.), respectively, whereas the systemic whole blood clearance values were 75.4 +/- 3.4 (n = 17) and 85.8 +/- 3.5 ml/min/kg (n = 21) (means +/- S.E.M.).","Disposition of hexobarbital in the rat. Estimation of ""first-pass"" elimination and influence of ether anesthesia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6864540/),min,11.6,20575,DB01355,Hexobarbital
,6864540,systemic whole blood clearance,"The average elimination half-lives were 13.5 +/- 0.8 (n = 17) and 11.6 +/- 1.9 min (n = 21) (means +/- S.E.M.), respectively, whereas the systemic whole blood clearance values were 75.4 +/- 3.4 (n = 17) and 85.8 +/- 3.5 ml/min/kg (n = 21) (means +/- S.E.M.).","Disposition of hexobarbital in the rat. Estimation of ""first-pass"" elimination and influence of ether anesthesia. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6864540/),[ml] / [kg·min],75.4,20576,DB01355,Hexobarbital
,6864540,systemic whole blood clearance,"The average elimination half-lives were 13.5 +/- 0.8 (n = 17) and 11.6 +/- 1.9 min (n = 21) (means +/- S.E.M.), respectively, whereas the systemic whole blood clearance values were 75.4 +/- 3.4 (n = 17) and 85.8 +/- 3.5 ml/min/kg (n = 21) (means +/- S.E.M.).","Disposition of hexobarbital in the rat. Estimation of ""first-pass"" elimination and influence of ether anesthesia. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6864540/),[ml] / [kg·min],85.8,20577,DB01355,Hexobarbital
,6864540,Oral availability,"Oral availability was found to be only 36%, which corresponds to an extraction ratio of 64%.","Disposition of hexobarbital in the rat. Estimation of ""first-pass"" elimination and influence of ether anesthesia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6864540/),%,36,20578,DB01355,Hexobarbital
,6864540,extraction ratio,"Oral availability was found to be only 36%, which corresponds to an extraction ratio of 64%.","Disposition of hexobarbital in the rat. Estimation of ""first-pass"" elimination and influence of ether anesthesia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6864540/),%,64,20579,DB01355,Hexobarbital
,6864540,protein binding,"The protein binding of hexobarbital in rat plasma amounted to 51.4 +/- 1.2% (mean +/- S.E.M., n = 15) and it was found not to be dependent on the plasma concentration of hexobarbital in the range encountered in vivo.","Disposition of hexobarbital in the rat. Estimation of ""first-pass"" elimination and influence of ether anesthesia. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6864540/),%,51.4,20580,DB01355,Hexobarbital
,1763520,whole-body,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,10.2,21980,DB01355,Hexobarbital
,1763520,whole-body,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,1.2,21981,DB01355,Hexobarbital
,1763520,half-life,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,10.2,21982,DB01355,Hexobarbital
,1763520,half-life,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,1.2,21983,DB01355,Hexobarbital
,1763520,half-life,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,0.37,21984,DB01355,Hexobarbital
,6660320,disposition half-life,"A theory of pharmacokinetic similarities is presented which states that both physiological and pharmacokinetic processes are biologically interrelated and governed by a master synchronization mechanism; consequently interspecies pharmacokinetic events frequently may be expressed as invariant values; e.g., hexobarbital disposition half-life is approximately the duration of 1,680 gut beats (time standard) regardless of mammalian species.",Interspecies pharmacokinetic scaling and the Dedrick plots. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6660320/),beats·gut,"1,680",34127,DB01355,Hexobarbital
,1768567,oral clearance,"2. The mean (+/- s.d.) oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],1.9,51649,DB01355,Hexobarbital
,1768567,oral clearance,"2. The mean (+/- s.d.) oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],1.8,51650,DB01355,Hexobarbital
,1768567,oral clearance,"2. The mean (+/- s.d.) oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],11.9,51651,DB01355,Hexobarbital
,1768567,oral clearance,"2. The mean (+/- s.d.) oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],10.7,51652,DB01355,Hexobarbital
,1768567,oral clearance,"3. In contrast, rifampicin treatment produced a larger and a differential increase in the oral clearance of R-(-) hexobarbitone in young and elderly subjects; an 89 fold change in the young (15.6 +/- 16.4 to 1146.7 +/- 1478.0 ml min-1 kg-1) and a 19 fold change (10.3 +/- 3.0 to 199.9 +/- 98.1 ml min-1 kg-1) in the elderly.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],15.6,51653,DB01355,Hexobarbital
,1768567,oral clearance,"3. In contrast, rifampicin treatment produced a larger and a differential increase in the oral clearance of R-(-) hexobarbitone in young and elderly subjects; an 89 fold change in the young (15.6 +/- 16.4 to 1146.7 +/- 1478.0 ml min-1 kg-1) and a 19 fold change (10.3 +/- 3.0 to 199.9 +/- 98.1 ml min-1 kg-1) in the elderly.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],1146.7,51654,DB01355,Hexobarbital
,1768567,oral clearance,"3. In contrast, rifampicin treatment produced a larger and a differential increase in the oral clearance of R-(-) hexobarbitone in young and elderly subjects; an 89 fold change in the young (15.6 +/- 16.4 to 1146.7 +/- 1478.0 ml min-1 kg-1) and a 19 fold change (10.3 +/- 3.0 to 199.9 +/- 98.1 ml min-1 kg-1) in the elderly.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],10.3,51655,DB01355,Hexobarbital
,1768567,oral clearance,"3. In contrast, rifampicin treatment produced a larger and a differential increase in the oral clearance of R-(-) hexobarbitone in young and elderly subjects; an 89 fold change in the young (15.6 +/- 16.4 to 1146.7 +/- 1478.0 ml min-1 kg-1) and a 19 fold change (10.3 +/- 3.0 to 199.9 +/- 98.1 ml min-1 kg-1) in the elderly.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],199.9,51656,DB01355,Hexobarbital
,3770011,U,"Urinary recovery of OH-HB, K-HB and DMBA following i.a. administration of OH-HB (75%) was more complete than the recovery following i.a. administration of K-HB (52%).",Disposition of allylic oxidation pathway metabolites of racemic hexobarbital in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770011/),%,75,54438,DB01355,Hexobarbital
,849678,elimination half-life,The average elimination half-life of hexobarbital had decreased from 407 to 171 min and its metabolic clearance had increased almost threefold.,Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/849678/),min,407 to 171,65632,DB01355,Hexobarbital
,849678,elimination half-life,"In contrast, the average elimination half-life of antipyrine was virtually the same on both occasions (6.9 and 7.2 hr) and there was no change in metabolic clearance.",Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/849678/),h,6.9,65633,DB01355,Hexobarbital
,849678,elimination half-life,"In contrast, the average elimination half-life of antipyrine was virtually the same on both occasions (6.9 and 7.2 hr) and there was no change in metabolic clearance.",Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/849678/),h,7.2,65634,DB01355,Hexobarbital
,3730526,plasma half-lives,"Mean plasma half-lives were 3.2 +/- 0.1 h, and salivary half-lives 3.3 +/- 0.2 h.",Pharmacokinetics of orally administered hexobarbital in plasma and saliva of healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730526/),h,3.2,81343,DB01355,Hexobarbital
,3730526,salivary half-lives,"Mean plasma half-lives were 3.2 +/- 0.1 h, and salivary half-lives 3.3 +/- 0.2 h.",Pharmacokinetics of orally administered hexobarbital in plasma and saliva of healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730526/),h,3.3,81344,DB01355,Hexobarbital
,3730526,plasma clearance,Mean plasma clearance was 22.9 +/- 2.3 1 h-1.,Pharmacokinetics of orally administered hexobarbital in plasma and saliva of healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730526/),[1] / [h],22.9,81345,DB01355,Hexobarbital
,3730526,salivary levels,Mean salivary levels were 34 per cent of plasma levels.,Pharmacokinetics of orally administered hexobarbital in plasma and saliva of healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730526/),%,34,81346,DB01355,Hexobarbital
,3730526,Sal,"Salivary pH was constant throughout the experiment, 7.06 +/- 0.09.",Pharmacokinetics of orally administered hexobarbital in plasma and saliva of healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730526/),,7.06,81347,DB01355,Hexobarbital
,3730526,percentage of protein binding,"The percentage of protein binding calculated from saliva over plasma ratios was in reasonable agreement with in vitro data of equilibrium dialysis, 64.1 +/- 2.6 per cent and 65.9 +/- 0.8 per cent, respectively.",Pharmacokinetics of orally administered hexobarbital in plasma and saliva of healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730526/),%,64.1,81348,DB01355,Hexobarbital
,3730526,percentage of protein binding,"The percentage of protein binding calculated from saliva over plasma ratios was in reasonable agreement with in vitro data of equilibrium dialysis, 64.1 +/- 2.6 per cent and 65.9 +/- 0.8 per cent, respectively.",Pharmacokinetics of orally administered hexobarbital in plasma and saliva of healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730526/),%,65.9,81349,DB01355,Hexobarbital
,6134816,elimination half-lives,"In control rats (n = 8) elimination half-lives and intrinsic clearance values ranged between 13 to 28 min and 96 to 435 ml/min X kg for hexobarbital and between 8 to 21 min and 84 to 371 ml/min X kg for heptabarbital, respectively.",Pharmacokinetics of simultaneously administered hexobarbital and heptabarbital in rats: an alternative approach to metabolic correlation studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6134816/),min,13 to 28,82642,DB01355,Hexobarbital
,6134816,intrinsic clearance,"In control rats (n = 8) elimination half-lives and intrinsic clearance values ranged between 13 to 28 min and 96 to 435 ml/min X kg for hexobarbital and between 8 to 21 min and 84 to 371 ml/min X kg for heptabarbital, respectively.",Pharmacokinetics of simultaneously administered hexobarbital and heptabarbital in rats: an alternative approach to metabolic correlation studies. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6134816/),[ml] / [kg·min],96 to 435,82643,DB01355,Hexobarbital
,3767526,CL0-120app,"After a dose of 50 mg/kg the CL0-120app was 34.8 +/- 5.9 ml/min/kg when administered i.a. and 80.4 +/- 7.5 ml/min/kg when administered via the portal vein, thus affording an estimate of 0.64 +/- 0.12 for the hepatic extraction ratio.",Non-linear pharmacokinetics of sparteine in the rat. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767526/),[ml] / [kg·min],34.8,103953,DB01355,Hexobarbital
,3767526,CL0-120app,"After a dose of 50 mg/kg the CL0-120app was 34.8 +/- 5.9 ml/min/kg when administered i.a. and 80.4 +/- 7.5 ml/min/kg when administered via the portal vein, thus affording an estimate of 0.64 +/- 0.12 for the hepatic extraction ratio.",Non-linear pharmacokinetics of sparteine in the rat. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767526/),[ml] / [kg·min],80.4,103954,DB01355,Hexobarbital
,3767526,hepatic extraction ratio,"After a dose of 50 mg/kg the CL0-120app was 34.8 +/- 5.9 ml/min/kg when administered i.a. and 80.4 +/- 7.5 ml/min/kg when administered via the portal vein, thus affording an estimate of 0.64 +/- 0.12 for the hepatic extraction ratio.",Non-linear pharmacokinetics of sparteine in the rat. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767526/),,0.64,103955,DB01355,Hexobarbital
,3767526,intrinsic clearance,"In support of this, the intrinsic clearance of orally administered hexobarbital (25 mg/kg) was determined 5 and 50 min after i.a. administered SP-sulphate (50 mg/kg), and decreased from 343 +/- 18 to 220 +/- 36 ml/min/kg (p less than 0.05).",Non-linear pharmacokinetics of sparteine in the rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767526/),[ml] / [kg·min],343,103956,DB01355,Hexobarbital
,3767526,intrinsic clearance,"In support of this, the intrinsic clearance of orally administered hexobarbital (25 mg/kg) was determined 5 and 50 min after i.a. administered SP-sulphate (50 mg/kg), and decreased from 343 +/- 18 to 220 +/- 36 ml/min/kg (p less than 0.05).",Non-linear pharmacokinetics of sparteine in the rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767526/),[ml] / [kg·min],220,103957,DB01355,Hexobarbital
,3917507,Ki,Piperine caused noncompetitive inhibition of hepatic microsomal AHH from the untreated and 3-methylcholanthrene-treated rats with a Ki of 30 microM which was close to the apparent Km of AHH observed in the controls.,Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3917507/),μM,30,133221,DB01355,Hexobarbital
,3917507,apparent Km,"Similarly, the kinetics of inhibition of ethylmorphine-N-demethylase from control rat liver microsomes exhibited noncompetitive inhibition with an apparent Km of 0.8 mM and Ki of 35 microM.",Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3917507/),mM,0.8,133222,DB01355,Hexobarbital
,3917507,Ki,"Similarly, the kinetics of inhibition of ethylmorphine-N-demethylase from control rat liver microsomes exhibited noncompetitive inhibition with an apparent Km of 0.8 mM and Ki of 35 microM.",Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3917507/),μM,35,133223,DB01355,Hexobarbital
,6849782,plasma elimination half-life,2 The mean plasma elimination half-life of hexobarbitone was 3.7 +/- 0.9 h (n = 6).,Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849782/),h,3.7,136982,DB01355,Hexobarbital
,6849782,volume of distribution,"Assuming complete absorption, the volume of distribution and the metabolic clearance were 81.3 +/- 20.5 1 and 16.4 +/- 2.9 1/h, respectively.",Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849782/),1,81.3,136983,DB01355,Hexobarbital
,6849782,metabolic clearance,"Assuming complete absorption, the volume of distribution and the metabolic clearance were 81.3 +/- 20.5 1 and 16.4 +/- 2.9 1/h, respectively.",Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849782/),[1] / [h],16.4,136984,DB01355,Hexobarbital
,6849782,maximal plasma concentration,The mean maximal plasma concentration was 7.1 +/- 2.1 micrograms/ml and was reached 1.2 +/- 0.4 h after drug administration.,Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849782/),[μg] / [ml],7.1,136985,DB01355,Hexobarbital
,6849782,half-lives,"The half-lives of 3'-hydroxyhexobarbitone and 1,5-dimethylbarbituric acid, calculated from their renal excretion rate curves, amounted 5.2 +/- 0.9 and 6.6 +/- 1.3 h and were significantly longer than the half-life of hexobarbitone in plasma.",Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849782/),h,5.2,136986,DB01355,Hexobarbital
,6849782,half-lives,"The half-lives of 3'-hydroxyhexobarbitone and 1,5-dimethylbarbituric acid, calculated from their renal excretion rate curves, amounted 5.2 +/- 0.9 and 6.6 +/- 1.3 h and were significantly longer than the half-life of hexobarbitone in plasma.",Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849782/),h,6.6,136987,DB01355,Hexobarbital
,6849782,half-life,The half-life of 3'-ketohexobarbitone was 4.2 +/- 0.8 h.,Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849782/),h,4.2,136988,DB01355,Hexobarbital
,6849782,maximal rate,3'-Hydroxy- and 3'-ketohexobarbitone were excreted with a maximal rate at 2.2 +/- 0.8 and 2.8 +/- 0.4 h respectively.,Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849782/),h,2.2,136989,DB01355,Hexobarbital
,6849782,maximal rate,3'-Hydroxy- and 3'-ketohexobarbitone were excreted with a maximal rate at 2.2 +/- 0.8 and 2.8 +/- 0.4 h respectively.,Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849782/),h,2.8,136990,DB01355,Hexobarbital
,1233266,elimination half-life,The average elimination half-life of hexobarbital had decreased from 325 to 122 min and of tolbutamide from 418 to 183 min following rifampicin treatment.,Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233266/),min,325 to 122,144728,DB01355,Hexobarbital
,1233266,elimination half-life,The average elimination half-life of hexobarbital had decreased from 325 to 122 min and of tolbutamide from 418 to 183 min following rifampicin treatment.,Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233266/),min,418 to 183,144729,DB01355,Hexobarbital
,7029928,plasma elimination half-life,"3. The mean plasma elimination half-life of 1',2'-epoxyhexobarbital after intra-arterial administration to the rat was 13.7 +/- 1.5 min (mean +/-S.D.; n = 3).","The metabolic fate of 1',2'-epoxyhexobarbital in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7029928/),min,13.7,145850,DB01355,Hexobarbital
,7029928,total body clearance,"A total body clearance of 35.2 +/- 9.6 ml/min (mean +/- S.D.) was calculated, which includes renal clearance of unchanged epoxide.","The metabolic fate of 1',2'-epoxyhexobarbital in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7029928/),[ml] / [min],35.2,145851,DB01355,Hexobarbital
,1686651,half-life,Higher doses of the levo enantiomer prolonged aminopyrine half-life to 78 (1 mg/kg) and 162 min. (10 mg/kg).,Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,78,146690,DB01355,Hexobarbital
,1686651,half-life,Higher doses of the levo enantiomer prolonged aminopyrine half-life to 78 (1 mg/kg) and 162 min. (10 mg/kg).,Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,162,146691,DB01355,Hexobarbital
,1686651,sleeping time,"The hexobarbital sleeping time was prolonged by the dose of 1 mg/kg of the levo enantiomer (128 min. versus 20 min. in controls), while the dose of 0.1 mg/kg had no effect (23 versus 20 min.).",Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,128,146692,DB01355,Hexobarbital
,1686651,sleeping time,"The hexobarbital sleeping time was prolonged by the dose of 1 mg/kg of the levo enantiomer (128 min. versus 20 min. in controls), while the dose of 0.1 mg/kg had no effect (23 versus 20 min.).",Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,20,146693,DB01355,Hexobarbital
,1686651,sleeping time,"The hexobarbital sleeping time was prolonged by the dose of 1 mg/kg of the levo enantiomer (128 min. versus 20 min. in controls), while the dose of 0.1 mg/kg had no effect (23 versus 20 min.).",Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,23,146694,DB01355,Hexobarbital
,3368506,area under the blood concentration-time curve (AUC),Infusion during 10 min resulted in an area under the blood concentration-time curve (AUC) of 556 +/- 83 micrograms.min/ml and a clearance of 83 +/- 13 ml/min.,Influence of the rate of hepatic portal vein infusion on hexobarbital pharmacokinetics in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3368506/),[min·μg] / [ml],556,157187,DB01355,Hexobarbital
,3368506,clearance,Infusion during 10 min resulted in an area under the blood concentration-time curve (AUC) of 556 +/- 83 micrograms.min/ml and a clearance of 83 +/- 13 ml/min.,Influence of the rate of hepatic portal vein infusion on hexobarbital pharmacokinetics in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3368506/),[ml] / [min],83,157188,DB01355,Hexobarbital
,6473507,Blood elimination half-lives,"Blood elimination half-lives of AP and HB were more than four times longer in PCS rats than in control rats, increasing from 63.7 +/- 3.9 to 291 +/- 66 min, and from 20.1 +/- 1.8 to 84.2 +/- 7.6 min, respectively.",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),min,63.7,159251,DB01355,Hexobarbital
,6473507,Blood elimination half-lives,"Blood elimination half-lives of AP and HB were more than four times longer in PCS rats than in control rats, increasing from 63.7 +/- 3.9 to 291 +/- 66 min, and from 20.1 +/- 1.8 to 84.2 +/- 7.6 min, respectively.",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),min,291,159252,DB01355,Hexobarbital
,6473507,Blood elimination half-lives,"Blood elimination half-lives of AP and HB were more than four times longer in PCS rats than in control rats, increasing from 63.7 +/- 3.9 to 291 +/- 66 min, and from 20.1 +/- 1.8 to 84.2 +/- 7.6 min, respectively.",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),min,20.1,159253,DB01355,Hexobarbital
,6473507,Blood elimination half-lives,"Blood elimination half-lives of AP and HB were more than four times longer in PCS rats than in control rats, increasing from 63.7 +/- 3.9 to 291 +/- 66 min, and from 20.1 +/- 1.8 to 84.2 +/- 7.6 min, respectively.",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),min,84.2,159254,DB01355,Hexobarbital
,6473507,Intrinsic clearance of,"Intrinsic clearance of HB (CLint, HB) was 167 +/- 19 ml/min/kg in controls and 27 +/- 4 ml/min/kg in PCS rats (CLpcs, HB).",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),[ml] / [kg·min],167,159255,DB01355,Hexobarbital
,6473507,CLpcs,"Intrinsic clearance of HB (CLint, HB) was 167 +/- 19 ml/min/kg in controls and 27 +/- 4 ml/min/kg in PCS rats (CLpcs, HB).",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),[ml] / [kg·min],27,159256,DB01355,Hexobarbital
,6473507,Intrinsic clearance,"Intrinsic clearance of AP (CLint, AP) in control rats was 15.1 +/- 0.7 ml/min/kg and 5.9 +/- 0.7 ml/min/kg in PCS rats (CLpcs, AP).",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),[ml] / [kg·min],15.1,159257,DB01355,Hexobarbital
,6473507,Intrinsic clearance,"Intrinsic clearance of AP (CLint, AP) in control rats was 15.1 +/- 0.7 ml/min/kg and 5.9 +/- 0.7 ml/min/kg in PCS rats (CLpcs, AP).",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),[ml] / [kg·min],5.9,159258,DB01355,Hexobarbital
,6473507,CLpcs,"Intrinsic clearance of AP (CLint, AP) in control rats was 15.1 +/- 0.7 ml/min/kg and 5.9 +/- 0.7 ml/min/kg in PCS rats (CLpcs, AP).",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),[ml] / [kg·min],5.9,159259,DB01355,Hexobarbital
,1356493,T1/2,This is always the case if the research substance can be labelled practically carrier-free with a short-lived positron emitter such as 11C (T1/2 = 20 min) or if applicable 18F (T1/2 = 110 min).,[Applications of positron emission tomography (PET) to the measurement of regional cerebral pharmacokinetics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356493/),min,20,173031,DB01355,Hexobarbital
,1356493,T1/2,This is always the case if the research substance can be labelled practically carrier-free with a short-lived positron emitter such as 11C (T1/2 = 20 min) or if applicable 18F (T1/2 = 110 min).,[Applications of positron emission tomography (PET) to the measurement of regional cerebral pharmacokinetics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356493/),min,110,173032,DB01355,Hexobarbital
,8272405,tmax,Oral absorption of CI-966 in dogs given 1.39 mg/kg is rapid with a tmax of 0.7 hr.,"Pharmacokinetics, mass balance, and induction potential of a novel GABA uptake inhibitor, CI-966 HCl, in laboratory animals. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272405/),h,0.7,192753,DB01355,Hexobarbital
,8272405,tmax,"In rats given 5 mg/kg oral, a mean tmax of 4.0 hr was observed.","Pharmacokinetics, mass balance, and induction potential of a novel GABA uptake inhibitor, CI-966 HCl, in laboratory animals. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272405/),h,4.0,192754,DB01355,Hexobarbital
,8272405,elimination t1/2,"Following iv administration of the same respective doses, elimination t1/2 in dogs and rats averaged 1.2 and 4.5 hr.","Pharmacokinetics, mass balance, and induction potential of a novel GABA uptake inhibitor, CI-966 HCl, in laboratory animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272405/),h,1.2,192755,DB01355,Hexobarbital
,8272405,elimination t1/2,"Following iv administration of the same respective doses, elimination t1/2 in dogs and rats averaged 1.2 and 4.5 hr.","Pharmacokinetics, mass balance, and induction potential of a novel GABA uptake inhibitor, CI-966 HCl, in laboratory animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272405/),h,4.5,192756,DB01355,Hexobarbital
,8272405,Absolute oral bioavailability,Absolute oral bioavailability of CI-966 was 100% in both species.,"Pharmacokinetics, mass balance, and induction potential of a novel GABA uptake inhibitor, CI-966 HCl, in laboratory animals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272405/),%,100,192757,DB01355,Hexobarbital
,2630837,half-life,The half-life of hexobarbital in 30-month-old rats (39.9 +/- 4.1 min) was significantly higher than that of 3-month-old ones (21.3 +/- 3.8 min).,Pharmacokinetics of hexobarbital in young and old rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2630837/),min,39.9,196863,DB01355,Hexobarbital
,2630837,half-life,The half-life of hexobarbital in 30-month-old rats (39.9 +/- 4.1 min) was significantly higher than that of 3-month-old ones (21.3 +/- 3.8 min).,Pharmacokinetics of hexobarbital in young and old rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2630837/),min,21.3,196864,DB01355,Hexobarbital
,2630837,intrinsic clearance,"The intrinsic clearance, expressed as ml.min-1.kg-1 body weight, of hexobarbital in 30-month-old rats (20.2 +/- 6.6) was half that of the 3-month-old ones (39.5 +/- 7.6).",Pharmacokinetics of hexobarbital in young and old rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2630837/),[ml] / [kg·min],20.2,196865,DB01355,Hexobarbital
,2630837,intrinsic clearance,"The intrinsic clearance, expressed as ml.min-1.kg-1 body weight, of hexobarbital in 30-month-old rats (20.2 +/- 6.6) was half that of the 3-month-old ones (39.5 +/- 7.6).",Pharmacokinetics of hexobarbital in young and old rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2630837/),[ml] / [kg·min],39.5,196866,DB01355,Hexobarbital
,6519152,plasma elimination half-life,"The peak level of alaproclate was reached after about 1.5 h, and after a distribution phase, its plasma elimination half-life was between 3.0 and 3.5 h.",Influence of alaproclate on antipyrine metabolite formation in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519152/),h,3.0 and 3.5,197415,DB01355,Hexobarbital
,7773609,volume of distribution,"Following intraperitoneal administration of 35S-labelled oligodeoxynucleotides, volume of distribution for the phosphorothioate was 0.33 l/kg while the 5' cholesteryl-conjugate oligodeoxynucleotide was 0.12 l/kg.",Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7773609/),[l] / [kg],0.33,197571,DB01355,Hexobarbital
,7773609,volume of distribution,"Following intraperitoneal administration of 35S-labelled oligodeoxynucleotides, volume of distribution for the phosphorothioate was 0.33 l/kg while the 5' cholesteryl-conjugate oligodeoxynucleotide was 0.12 l/kg.",Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7773609/),[l] / [kg],0.12,197572,DB01355,Hexobarbital
,7773609,elimination half-life,"The elimination half-life was 23.2 and 55.4 hrs for cholesteryl-modified and unmodified oligodeoxynucleotides, respectively.",Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7773609/),h,23.2,197573,DB01355,Hexobarbital
,7773609,elimination half-life,"The elimination half-life was 23.2 and 55.4 hrs for cholesteryl-modified and unmodified oligodeoxynucleotides, respectively.",Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7773609/),h,55.4,197574,DB01355,Hexobarbital
,7773609,sleep times,"Hexobarbital sleep times, a measure of CYP2B1 enzyme activity in vivo, increased from 21.9 minutes in saline-treated animals to 29.5 minutes in cholesterol oligodeoxynucleotide-treated animals.",Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7773609/),min,21.9,197575,DB01355,Hexobarbital
,7773609,sleep times,"Hexobarbital sleep times, a measure of CYP2B1 enzyme activity in vivo, increased from 21.9 minutes in saline-treated animals to 29.5 minutes in cholesterol oligodeoxynucleotide-treated animals.",Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7773609/),min,29.5,197576,DB01355,Hexobarbital
,862650,elimination half-life,The average elimination half-life of hexobarbital had decreased from 624 to 262 min and that of tolbutamide from 292 to 160 min following rifampicin treatment.,Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/862650/),min,624 to 262,205510,DB01355,Hexobarbital
,862650,elimination half-life,The average elimination half-life of hexobarbital had decreased from 624 to 262 min and that of tolbutamide from 292 to 160 min following rifampicin treatment.,Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/862650/),min,292 to 160,205511,DB01355,Hexobarbital
,19863908,Half-life,"Half-life value of 61,8 h was found, being much longer than already published hexobarbital half-lives (between 3.2 h and 6.9 h).",[Human toxicokinetic of hexobarbital after acute multi-drug intoxication]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19863908/),h,"61,8",206338,DB01355,Hexobarbital
,19863908,half-lives,"Half-life value of 61,8 h was found, being much longer than already published hexobarbital half-lives (between 3.2 h and 6.9 h).",[Human toxicokinetic of hexobarbital after acute multi-drug intoxication]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19863908/),h,3.2,206339,DB01355,Hexobarbital
,19863908,half-lives,"Half-life value of 61,8 h was found, being much longer than already published hexobarbital half-lives (between 3.2 h and 6.9 h).",[Human toxicokinetic of hexobarbital after acute multi-drug intoxication]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19863908/),h,6.9,206340,DB01355,Hexobarbital
,25162217,plasma half-life,"EFV is characterized by a long plasma half-life (40-55 hours) with large interpatient variability, which raises the potential for individualization of therapy.",A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25162217/),h,40-55,211694,DB01355,Hexobarbital
>,25162217,recovery,Mean recovery was >64%.,A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25162217/),%,64,211695,DB01355,Hexobarbital
,7363932,half-life of,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),min,323,250135,DB01355,Hexobarbital
,7363932,half-life of,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),min,357,250136,DB01355,Hexobarbital
,7363932,half-life of,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),min,344,250137,DB01355,Hexobarbital
,7363932,clearances,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),[ml] / [kg·min],3.41,250138,DB01355,Hexobarbital
,7363932,clearances,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),[ml] / [kg·min],4.08,250139,DB01355,Hexobarbital
,7363932,clearances,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),[ml] / [kg·min],3.81,250140,DB01355,Hexobarbital
,3656350,ED50,"For example, following oral administration to mice, it antagonized maximal electroshock (MES) induced seizures with an ED50 of 1.7 mg/kg.","Discovery and anticonvulsant activity of the potent metabolic inhibitor 4-amino-N-(2,6-dimethylphenyl)-3,5-dimethylbenzamide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3656350/),[mg] / [kg],1.7,260000,DB01355,Hexobarbital
,3656350,oral ED50,"Both compounds antagonized MES-induced seizures after administration to mice; oral ED50 values for 3 and 4 were 3.5 and 5.6 mg/kg, respectively.","Discovery and anticonvulsant activity of the potent metabolic inhibitor 4-amino-N-(2,6-dimethylphenyl)-3,5-dimethylbenzamide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3656350/),[mg] / [kg],3.5,260001,DB01355,Hexobarbital
,3656350,oral ED50,"Both compounds antagonized MES-induced seizures after administration to mice; oral ED50 values for 3 and 4 were 3.5 and 5.6 mg/kg, respectively.","Discovery and anticonvulsant activity of the potent metabolic inhibitor 4-amino-N-(2,6-dimethylphenyl)-3,5-dimethylbenzamide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3656350/),[mg] / [kg],5.6,260002,DB01355,Hexobarbital
,3356087,oral clearance,Mean oral clearance (+/- SD) of d-hexobarbital (1.9 +/- 0.5 vs.,Age-associated stereoselective alterations in hexobarbital metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356087/),,1.9,273464,DB01355,Hexobarbital
,3356087,oral clearance,"However, despite wide intersubject variability, l-hexobarbital mean oral clearance (+/- SD) was approximately twofold greater in the young than in the elderly subjects (16.9 +/- 11.9 vs. 8.2 +/- 3.2 ml/min/kg; P less than 0.05).",Age-associated stereoselective alterations in hexobarbital metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356087/),[ml] / [kg·min],16.9,273465,DB01355,Hexobarbital
,3356087,oral clearance,"However, despite wide intersubject variability, l-hexobarbital mean oral clearance (+/- SD) was approximately twofold greater in the young than in the elderly subjects (16.9 +/- 11.9 vs. 8.2 +/- 3.2 ml/min/kg; P less than 0.05).",Age-associated stereoselective alterations in hexobarbital metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356087/),[ml] / [kg·min],8.2,273466,DB01355,Hexobarbital
,3356087,oral clearance ratio,This resulted in a significantly greater enantiomeric oral clearance ratio in the young when compared with the elderly subjects (8.3 +/- 3.4 vs. 4.7 +/- 1.4; P less than 0.01).,Age-associated stereoselective alterations in hexobarbital metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356087/),,8.3,273467,DB01355,Hexobarbital
,3356087,oral clearance ratio,This resulted in a significantly greater enantiomeric oral clearance ratio in the young when compared with the elderly subjects (8.3 +/- 3.4 vs. 4.7 +/- 1.4; P less than 0.01).,Age-associated stereoselective alterations in hexobarbital metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356087/),,4.7,273468,DB01355,Hexobarbital
,1164825,elimination half-life,The elimination half-life of hexobarbital was 490 +/- 186 min in the hepatitis patients and 261 +/- 69 min in the control group.,Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164825/),min,490,273538,DB01355,Hexobarbital
,1164825,elimination half-life,The elimination half-life of hexobarbital was 490 +/- 186 min in the hepatitis patients and 261 +/- 69 min in the control group.,Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164825/),min,261,273539,DB01355,Hexobarbital
